Loading...

Our Scientific Publications & Presentations

Home / Our Focus / Selected References

Our Scientific Publications & Presentations

Title
Evaluation of Baseline Risk Factors on Progression in Geographic AtrophyPost-hoc Analysis from the FILLY Study

View PDF
Speaker/
Author
Nathan Steinle
Conference/
Journal
Association for Research in Vision and Ophthalmology (ARVO)
Date
04/28/19

Title
Inhibition of C3 with APL-2 Results in Normalisation of Markers of Intravascular and Extravascular Haemolysis in Patients with Paroxysmal Nocturnal Haemoglobinuria

View PDF
Speaker/
Author
Raymond Wong
Conference/
Journal
British Society of Haematology
Date
04/01/19

Title
Inhibiting Complement C3 with APL-2 Controls Haemolysis and Increases Hemoglobin Levels in Patients With Autoimmune Hemolytic Anemia (AIHA)

View PDF
Speaker/
Author
Bruno Fattizzo
Conference/
Journal
British Society of Haematology
Date
04/02/19

Title
Poster: Inhibition of C3 With APL-2 Results in Normalization of Markers of Intravascular and Extravascular Hemolysis in Subjects with Paroxysmal Nocturnal Hemoglobinuria (PNH)

View PDF
Speaker/
Author
Raymond Wong
Conference/
Journal
American Society of Hematology (ASH)
Date
12/02/18

Title
Poster: Inhibition of C3 With APL-2 Controls Hemolysis and Increases Hemoglobin Levels in Subjects With Autoimmune Hemolytic Anemia (AIHA)

View PDF
Speaker/
Author
Morie Gertz
Conference/
Journal
ASH
Date
12/02/18

Title
Presentation: 2018 Complement-based Drug Development Summit Presentation

View PDF
Speaker/
Author
Lukas Scheibler
Conference/
Journal
Complement-based Drug Development Summit
Date
11/14/18

Title
Presentation: APL-2 Treatment For Geographic Atrophy: Long-term Results

View PDF
Speaker/
Author
David Brown
Conference/
Journal
American Association of Ophthalmology
Date
10/27/18

Title
Presentation: Disease Burden in Geographic Atrophy

View PDF
Speaker/
Author
Usha Chakravarthy
Conference/
Journal
EURETINA
Date
09/22/18

Title
Presentation: Complement C3 Inhibition in Geographic Atrophy

View PDF
Speaker/
Author
Jason Slakter
Conference/
Journal
EURETINA
Date
09/22/18

Title
Presentation: APL-2, a Complement C3 Inhibitor, Slows the Growth of Geographic Atrophy Secondary to AMD: 18-Month Results

View PDF
Speaker/
Author
David Brown
Conference/
Journal
Retina Society
Date
09/13/18

Title
Presentation: APL-2 in GA: Phase II FILLY Trial 18-Month Results

View PDF
Speaker/
Author
Nathan Steinle
Conference/
Journal
American Society of Retina Specialists (ASRS)
Date
07/23/18

Title
Poster: APL-2, a complement C3 inhibitor, slows the growth of geographic atrophy secondary to AMD: 18-month results of a phase 2 trial (FILLY).

View PDF
Speaker/
Author
Charles Wykoff
Conference/
Journal
The Association for Research in Vision and Ophthalmology (ARVO)
Date
04/30/18

Title
Presentation: APL-2 (pegcetacoplan)Geographic atrophy Preliminary 18-month results

View PDF
Speaker/
Author
Rishi Singh
Conference/
Journal
Macula Society
Date
02/23/18

Title
Presentation: APL-2 in Geographic Atrophy12-Month Results

View PDF
Speaker/
Author
Jeffrey Heier
Conference/
Journal
Atlantic Coast Retina
Date
01/12/18

Title
Presentation: APL-2, a complement C3 inhibitor, to treat patients with paroxysmal nocturnal hemoglobinuria

View PDF
Speaker/
Author
Delphine El Mehdi
Conference/
Journal
Complement-based Drug Development Summit
Date
11/15/17

Title
Presentation: APL-2 in Geographic Atrophy12-Month Results

View PDF
Speaker/
Author
David Brown
Conference/
Journal
AAO
Date
11/10/17

Title
Poster: APL-2, a complement C3 inhibitor, may potentially reduce both intravascular and extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria

View PDF
Speaker/
Author
Delphine El Mehdi
Conference/
Journal
European Meeting on Complement in Human Disease (EMCHD)
Date
09/11/17

Title
Abstract: Repeat Measurements of Complement proteins C3a and C5a in COPD patients

View PDF
Speaker/
Author
Thomas Southworth
Conference/
Journal
European Respiratory Society
Date
09/10/17

Title
Poster: Prediction of duration of C3 inhibition with APL‐2 in human eyes using a PK/PD binding model

View PDF
Speaker/
Author
Matthias Machacek
Conference/
Journal
ARVO
Date
05/07/17

Title
Presentation: Complement: the next frontier in immunology?

View PDF
Speaker/
Author
Cedric Francois
Conference/
Journal
Biotecnologia
Date
05/17

Title
Poster: APL-2, a Complement C3 Inhibitor for the Potential Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH): Phase I Data from Two Completed Studies in Healthy Volunteers

View PDF
Speaker/
Author
Federico Grossi
Conference/
Journal
American Society of Hematology (ASH)
Date
12/03/16

Title
Presentation: APL-2 and complement inhibition; a potential treatment of PNH and other complement-mediated diseases

View PDF
Speaker/
Author
Caroline Vega
Conference/
Journal
Boulder Peptide Symposium
Date
09/27/16

Title
Presentation: Complement Immunotherapy using compstatin derivatives

View PDF
Speaker/
Author
Delphine El Mehdi
Conference/
Journal
Aegean Complement Theraputics
Date
06/29/16

Title
Presentation: Complement C3 Inhibition in AMD

View PDF
Speaker/
Author
Cedric Francois
Conference/
Journal
Angiogenesis
Date
02/06/16

Title
Publication: Small peptides for inhibition of central component of immunity: the complement system

View PDF
Speaker/
Author
Delphine El Mehdi & Pascal Deschatelets
Conference/
Journal
Chemistry Today
Date
2016

Title
Poster: Ocular Coherence Tomography Supports an Investigational New DrugApplication for a C3 Complement Inhibitor Targeting Macular Degeneration

View PDF
Speaker/
Author
Margaret Collins
Conference/
Journal
Society Of Toxicology (SOT)
Date
03/23/15

Title
Publication: Therapeutic Thought

View PDF
Speaker/
Author
Cedric Francois & Pascal Deschatelets
Conference/
Journal
Complement Immunotherapy
Date
05/2016

Title
Poster: Red Cell Complement Loading In PNH Patients On Eculizumab Is Associated With a C3 Polymorphism Which Influences C3 Function, Predicts For Increased Extravascular Haemolysis and Provides a Rationale For C3 Inhibition

View PDF
Speaker/
Author
Praveen Kaudlay
Conference/
Journal
ASH
Date
12/08/13



Apellis logo
© Apellis Pharmaceuticals 2019.